Hinova Pharma, a Chinese drug developer has raised RMB1 billion ($147 million) in Series C funding from Shenzhen Investment, Hong Kong-listed Tigermed, Huarong Rongde Asset Management, CCB Internationa, and a fund run by Sinopharm Group and CICC Capital.
Hongtai Capital, Sealand Innovation, Infinity Group, Founder H Fund, Dinova Capital, Shenzhen Qindao Capital and Zhongke Rongxin Technology also participated, according to a statement. Founded in 2013,...
Australia-founded beverages maker Lyre’s has raised $11.5 million in seed funding with a view to helping non-alcoholic spirits follow in the footsteps of alternative protein
Chinese online-to-offline (O2O) medicine retailer Dingdang Kuaiyao has raised RMB1 billion ($150 million) in an extended Series B round featuring Dragon Gate Investment Partners.
Sinovation Ventures is looking to raise $1 billion for a growth-stage private equity fund that will focus on introducing artificial intelligence technologies (AI) to traditional industries.
SAIF Partners India has closed its fourth fund at $400 million within a few weeks of launch and rebranded as Elevation Capital.